AXIM Biotechnologies, Inc. announced the appointment of Kurt Phinney as its new Chief Operating Officer. Phinney, a seasoned healthcare operations executive, will play a vital role in scaling and optimizing AXIM's manufacturing operations for its proprietary ophthalmological diagnostic assays to meet the rising demand. With an extensive background in healthcare operations management and scaling diagnostic companies, Phinney brings valuable expertise to AXIM.

In previous roles, he successfully reduced costs, increased capacity, and shortened production time, boosting manufacturing output from 11,000 assays to an impressive 225,000 assays per week. Phinney also enjoys a track record of implementing and managing Quality Management Systems (QMS) and has successfully teamed to obtain CLIA-waiver applications with the FDA, which he aims to replicate at AXIM. The addition of Kurt Phinney to the team aims to increase this capacity by at least 50% by fourth quarter 2023.

This expansion is essential to meet the growing demand driven by AXIM's commercialization partner, which is actively securing clinics across the country for the implementation of AXIM's diagnostic assays.